Dengue immunity after infection or vaccination
Protective immunity following dengue virus natural infections and vaccination
This project looks at how past dengue infections or vaccines change your immune system's ability to protect you from future dengue.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project ID | NIH-11111751 on NIH RePORTER |
What this research studies
Researchers collect blood samples and clinical information from people who had dengue or received dengue vaccines and run lab tests on antibodies, B cells, and T cells to see how the immune system responds. They compare immune responses across the four dengue serotypes and link lab findings to who became ill or stayed well. The team uses advanced virology and immune assays together with clinical and epidemiological data to search for markers that predict protection or higher risk of severe disease. The work focuses on "imprinting"—how earlier exposures shape later immunity—to help guide safer vaccine strategies.
Who could benefit from this research
Good fit: Ideal participants are people in dengue-affected regions or vaccine recipients, especially those with prior documented dengue infection who can provide blood samples and health history.
Not a fit: People seeking immediate treatment for a current severe dengue infection or those with no dengue exposure are unlikely to receive direct medical benefit from participation.
Why it matters
Potential benefit: If successful, this work could help identify markers that predict who is protected or at risk and guide safer, more effective dengue vaccines and vaccine-use policies.
How similar studies have performed: Previous studies, including many publications from this team, have identified immune patterns linked to protection or risk but a fully reliable biomarker has not yet been established.
Where this research is happening
Berkeley, United States
- University of California Berkeley — Berkeley, United States (Active)
Researchers
- Principal investigator: Harris, Eva — University of California Berkeley
- Study coordinator: Harris, Eva
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.